How do you mix gonadorelin?

100 mcg of GnRH (Gonadorelin) from a 0.1 mg vial mixed with 1 mL is 100 units on a U-100 syringe.

Every vial at a glance. Pick a cell to draw it on the syringe.

Concentration is the vial's amount over its water; units are the dose over the concentration, times 100, on a U-100 syringe.
Vial1 mL of water
0.1 mg0.1 mg/mL: 100 mcg is 100 units

The UK label mixes one 100 microgram vial with 1 mL of water for injections, giving 100 micrograms/mL, and gives 100 micrograms, subcutaneously or intravenously, as its dose for adults and the elderly in a single-injection test of pituitary gonadotropin function.1

Vial strengths, diluent and syringe marks

The Canadian Lutrepulse monograph says a 10 mL vial of either 0.8 mg or 3.2 mg is reconstituted with 8 mL of the 0.9% sodium chloride diluent.2 A 2015 study by Li and colleagues of 22 young men with hypogonadotropic hypogonadism and 20 healthy controls dissolved 600 μg of gonadorelin in 3 mL of normal saline for a pump that gave the 22 men 10 μg per 90 min pulse, 160 μg a day, subcutaneously for 6 months; the controls were not treated.3

Worked from the UK label's figures (the label gives no syringe mark): 0.1 mg in 1 mL is 100 mcg/mL, so 100 mcg is 1 mL, or 100 units on a U-100 syringe.1

100 mcg of GnRH (Gonadorelin) from a 0.1 mg vial mixed with 1 mL is 100 units on a U-100 syringe.

The search did not locate a manufacturer page for the powder vial strengths people stock, or a label or leaflet for bacteriostatic water with a gonadorelin powder. No usable Milligram log figure for gonadorelin exists here; the figures are sourced figures and arithmetic only.

100 mcg of GnRH (Gonadorelin) from a 0.1 mg vial mixed with 1 mL is 100 units on a U-100 syringe.

Dose and schedule in labels and trials

For women with primary hypothalamic amenorrhea, the Canadian Lutrepulse monograph gives 5 µg every 90 minutes as the usual dose, and says its pivotal studies of 268 women used 0.5 to 40 µg/pulse at frequencies from 10 to 180 minutes, the most often used being 90 minutes.2 The search found no repeated needle-injection schedule in men; the trials used pump pulses.

TrialDose and schedulePeopleLength
Kliesch 19944GnRH 5-20 micrograms every 120 min subcutaneously; comparator hCG 1000-2500 IE twice per week plus hMG 75-150 IE three times per week, intramuscularly or subcutaneouslyTwenty-six men with hypogonadotropic hypogonadism across both arms; GnRH for men with hypothalamic disordersUntil sperm appeared in the ejaculate or pregnancy was induced
Zhang 20195Subcutaneous pump every 90 min, or hCG/hMGTwenty-eight men with congenital hypogonadotropic hypogonadism: ten on the pump, 18 on hCG/hMGUp to 24 months
Wang 202565 μg/90 min subcutaneously by pump, adjusted to testosterone, maximum 10 μg/90 minSeven male infants with congenital hypogonadotropic hypogonadism3-5 months

In the Zhang 2019 trial the pump dose rose to 15 μg every 90 min for one man with low testosterone, and was also increased for two others when testosterone fell below the lower limit of normal, and was lowered to 3 μg every 90 min for one man.5

With testosterone therapy or after a cycle

A 2026 narrative review of strategies for TRT-induced reproductive suppression rates gonadorelin as having limited clinical evidence for fertility restoration and limited clinical use, and says GnRH efficacy depends on pulsatile administration, whereas continuous exposure results in receptor downregulation and suppression of gonadotropin secretion.7 Searches of PubMed and ClinicalTrials.gov found no label or human trial of gonadorelin with testosterone therapy or after a cycle, so see the TRT guide and the gonadorelin page for the studies.

Storage before and after mixing

The UK label gives a shelf life of 3 years unopened below 25° C, and 24 hours after reconstitution: refrigerate, use within 1 day and discard what is unused.1 The Lutrepulse monograph says the unopened powder and sodium chloride are stable at room temperature (15°-30°C).2 A 1990 laboratory study by Wong and colleagues of the Lutrepulse product (not a human trial) found the lyophilized product stable for at least 18 months at 24 degrees C, and the reconstituted pump material for at least 45 days at 24 or 37 degrees C.8 A laboratory study by Hahn and colleagues (not a human trial) found no appreciable loss of activity in GnRH solution after 4 weeks of storage at either 4 degrees C or room temperature.9 The search found no storage statement for a compounded or research-grade gonadorelin powder vial after mixing with bacteriostatic water.

Frequently asked questions

Where is gonadorelin injected?

For its pump, a second Canadian Lutrepulse monograph says that normally the abdomen is the preferred site for attaching the POD, with a new site at least 2.5 cm from the previous one for each new POD.10 The search found no stated injection site for a repeated needle injection.

Is gonadorelin approved for people?

A narrative review says gonadorelin was FDA approved but is no longer manufactured.11 The Cystorelin veterinary label says it is not for use in humans.12 A DailyMed search found no current FDA-approved human gonadorelin product.

What safety information do the labels give?

The UK label says no hypersensitivity reactions had been encountered to date after a single 100 micrograms dose used for diagnosis, but that rare instances of hypersensitivity reactions have been reported, and it asks for careful observation of patients in whom re-administration is considered, particularly by the intravenous route.1 The Lutrepulse monograph says most adverse effects are associated with the parenteral route, and that adverse reactions were reported in about 10% of treatment regimens in its pivotal trials in 268 women.2

References

  1. medicines.org.uk (EMC). Gonadorelin 100 micrograms powder for solution for injection - Summary of Product Characteristics (SmPC) - print friendly - (emc). medicines.org.uk
  2. Health Canada DPD. Microsoft Word - LUTREPULSE.apm.doc. pdf.hres.ca
  3. International Journal of Endocrinology (full text, PubMed Central). Changes in Bone Mineral Density and Metabolic Parameters after Pulsatile Gonadorelin Treatment in Young Men with Hypogonadotropic Hypogonadism. 2015. pmc.ncbi.nlm.nih.gov
  4. PubMed. High efficacy of gonadotropin or pulsatile gonadotropin-releasing hormone treatment in hypogonadotropic hypogonadal men. 1994. pubmed.ncbi.nlm.nih.gov
  5. American Journal of Men's Health (full text, PubMed Central). The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men. 2018. pmc.ncbi.nlm.nih.gov
  6. Endocrine Connections (full text, PubMed Central). Efficacy and safety of pulsatile GnRH pump therapy in male infants with congenital hypogonadotropic hypogonadism. 2025. pmc.ncbi.nlm.nih.gov
  7. Frontiers in Reproductive Health (full text, PubMed Central). Emerging peptide and neuroendocrine strategies for TRT-induced reproductive suppression and functional male hypogonadism: a narrative review. 2026. pmc.ncbi.nlm.nih.gov
  8. PubMed. Stability and purity profile of gonadorelin acetate: a high-purity gonadotropin-releasing hormone. 1990. pubmed.ncbi.nlm.nih.gov
  9. PubMed. The stability of synthetic gonadotropin-releasing hormone in solution. 1987. pubmed.ncbi.nlm.nih.gov
  10. Health Canada DPD. [Product Monograph Template - Standard]. pdf.hres.ca
  11. PubMed. Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review. 2026. pubmed.ncbi.nlm.nih.gov
  12. DailyMed. CYSTORELIN ® (gonadorelin) 50 mcg/mL gonadorelin diacetate tetrahydrate Injectable Solution. 2025. dailymed.nlm.nih.gov